Department of Radiation Oncology, University of Florida College of Medicine, Jacksonville, Florida.
Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts.
Int J Radiat Oncol Biol Phys. 2022 Feb 1;112(2):335-341. doi: 10.1016/j.ijrobp.2021.09.030. Epub 2021 Sep 29.
Few studies report outcomes in children treated with radiation for nonmyxopapillary ependymoma of the spinal cord, and little evidence exists to inform decisions regarding target volume and prescription dose. Moreover, virtually no mature outcome data exist on proton therapy for this tumor. We describe our combined institutional experience treating pediatric classical/anaplastic ependymoma of the spinal cord with proton therapy.
Between 2008 and 2019, 14 pediatric patients with nonmetastatic nonmyxopapillary grade II (n = 6) and grade III (n = 8) spinal ependymoma received proton therapy. The median age at radiation was 14 years (range, 1.5-18 years). Five tumors arose within the cervical cord, 3 within the thoracic cord, and 6 within the lumbosacral cord. Before radiation therapy, 3 patients underwent subtotal resection, and 11 underwent gross-total or near total resection. Two patients received chemotherapy. For radiation, the clinical target volume received 50.4 Gy (n = 8), 52.2 (n = 1), or 54 Gy (n = 5), with the latter receiving a boost to the gross tumor volume after the initial 50.4 Gy, modified to respect spinal cord tolerance.
With a median follow-up of 6.3 years (range, 1.5-14.8 years), no tumors progressed. Although most patients experienced neurologic sequela after surgery, only 1 developed additional neurologic deficits after radiation: An 18-year-old male who received 54 Gy after gross total resection of a lumbosacral tumor developed grade 2 erectile dysfunction. There were 2 cases of musculoskeletal toxicity attributable to surgery and radiation. At analysis, no patient had developed cardiac, pulmonary, or other visceral organ complications or a second malignancy.
Radiation to a total dose of 50 to 54 Gy can be safely delivered and plays a beneficial role in the multidisciplinary management of children with nonmyxopapillary spinal cord ependymoma. Proton therapy may reduce late radiation effects and is not associated with unexpected spinal cord toxicity.
鲜有研究报道接受放射治疗的非黏液性髓上皮瘤患儿的结局,且针对靶区体积和处方剂量的决策,证据也十分有限。此外,质子治疗该肿瘤的成熟疗效数据几乎不存在。我们介绍了机构治疗儿童脊髓经典/间变室管膜瘤的联合经验。
2008 年至 2019 年间,14 例非转移性非黏液性髓上皮瘤Ⅱ级(n=6)和Ⅲ级(n=8)脊髓室管膜瘤患儿接受了质子治疗。放疗时的中位年龄为 14 岁(范围 1.5-18 岁)。5 例肿瘤位于颈髓,3 例位于胸髓,6 例位于腰骶髓。放疗前,3 例患者接受了次全切除术,11 例患者接受了大体全切除或近全切除术。2 例患者接受了化疗。对于放疗,8 例患者的临床靶区接受 50.4 Gy,1 例患者接受 52.2 Gy,5 例患者接受 54 Gy,其中 5 例患者在初始 50.4 Gy 后接受大体肿瘤体积的加量,以尊重脊髓耐受。
中位随访 6.3 年(范围 1.5-14.8 年),无肿瘤进展。尽管大多数患者在手术后出现神经后遗症,但只有 1 例患者在放疗后出现新的神经缺损:1 例 18 岁男性,腰骶部肿瘤接受大体全切除后接受 54 Gy 放疗,出现 2 级勃起功能障碍。有 2 例肌肉骨骼毒性归因于手术和放疗。在分析时,没有患者出现心脏、肺部或其他内脏器官并发症或第二恶性肿瘤。
总剂量 50-54 Gy 的放疗可安全进行,并在非黏液性髓上皮瘤儿童的多学科治疗中发挥有益作用。质子治疗可能减少迟发性辐射效应,且与意外的脊髓毒性无关。